| Literature DB >> 35756720 |
Satoru Ishii1, Motoyasu Iikura1, Yuriko Sugiura1, Rei Matsuki1, Shinyu Izumi1, Masayuki Hojo1, Haruhito Sugiyama1.
Abstract
Bronchial thermoplasty (BT) is a type of bronchoscopic treatment specifically used for patients with severe asthma. Most severe asthmatics receive systemic steroids and are at risk of being immunocompromised. This raises the clinical question of whether or not BT can be effectively and safely performed in such patients. Herein, we report a case highlighting the effectiveness and safety of BT in a patient with severe persistent bronchial asthma and Pseudomonas aeruginosa infection. We performed BT on a 46-year-old woman undergoing treatment for severe persistent asthma with inhaled steroids and 20 mg prednisolone orally. Although she was deemed to be infection-free before the procedure, culture of endobronchial secretions obtained during the first BT procedure grew Pseudomonas aeruginosa. After the first BT, she was given clarithromycin 400 mg orally daily. The amount of sputum decreased with each BT session, and sputum culture for Pseudomonas aeruginosa turned negative by the third BT session. Respiratory function tests showed 23.7% improvement in % post-bronchodilator forced expiratory volume in 1.0 s (%FEV1.0) and the asthma quality of life questionnaire (AQLQ) score increased by 2.41 points after the third BT. Bronchial wall thickness decreased and infiltrative shadows on CT disappeared after the three BT sessions, along with decrease in the amount of purulent sputum. Improvement in her asthma symptoms, after three BT sessions allowed decrease in the prednisolone dose. We report the effectiveness of BT and infection control in a severe asthmatic with Pseudomonas aeruginosa infection.Entities:
Keywords: %FEV1, % post-bronchodilator forced expiratory volume in 1.0 s; %FEV1.0; AQLQ; AQLQ, asthma quality of life questionnaire; BT; BT, Bronchial thermoplasty; CT, chest computed tomography; Clarithromycin; FeNO, Fractional exhaled nitric oxide; HRCT, High-resolution computed tomography; Pseudomonas aeruginosa; Severe asthma
Year: 2022 PMID: 35756720 PMCID: PMC9213246 DOI: 10.1016/j.rmcr.2022.101685
Source DB: PubMed Journal: Respir Med Case Rep ISSN: 2213-0071
Laboratory findings on admission.
| <Peripheral blood> | <Biochemistry> | <Serology> | |||
|---|---|---|---|---|---|
| WBC | 13400/μl | TP | 7.1 g/dl | Procalcitonin | 0.04 ng/ml |
| Neu | 93.0% | Alb | 4.0 g/dl | IgE | 15.3 U/ml |
| Lym | 0% | AST | 16 U/L | Cedar | 3+ |
| Mon | 6.0% | ALT | 14 U/L | Tick | 2+ |
| Eos | 1.0% | LDH | 221 U/L | House dust | 1+ |
| Bas | 0% | BUN | 13 mg/dl | ||
| Hb | 15.1 g/dl | Cr | 0.5 mg/dl | ||
| Ht | 46.2% | CRP | 1.1 mg/dl | ||
| Plt | 27.0 × 104/μl | ||||
Fig. 1High-resolution computed tomography (HRCT) and bronchial thermoplasty (BT) findings; HRCT showed bronchial wall thickening and infiltrative shadows at the right inferior lobe before the first BT (A, B, C). Endobronchial inspection during the first BT procedure was significant for a large amount of yellow secretion in the right inferior lobe (D). HRCT performed after three BT sessions showed a decrease in bronchial wall thickness and disappearance of infiltrative shadows in the right inferior lobe (E, F, G). Endobronchial inspection during the third BT procedure did not show purulent sputum in the right inferior lobe (H). . (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2Time course of % post-bronchodilator forced expiratory volume in 1.0 s (%FEV1), cumulative sputum volume, results of sputum bacterial culture, and clarithromycin treatment; Pulmonary function improved after the third bronchial thermoplasty (BT) session. Cumulative sputum volume and results of sputum bacterial culture for Pseudomonas aeruginosa improved after the third BT session.